Federico Grossi
CIK 1720634 · Chief Medical Officer · last filed 2025-01-07
Federico Grossi is a Chief Medical Officer who has filed 63 SEC Form 4 insider transactions across 2 companies since 2018. The most recent filing, for UBX, was dated Jan 7, 2025. Across all open-market trades the lifetime net is −$2.2M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
63
-$2.23M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Unity Biotechnology, Inc. (UBX) Delisted | Chief Medical Officer | — | $0.20 | — | $0 | 1 | 2025-01-07 |
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Medical Officer | 94,884 | $41.03 | $3.89M | -$2.23M | 62 | 2023-01-09 |
Recent Filings
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-07 | Unity Biotechnology, Inc. (UBX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-09 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,500 | -$122.0K | EDGAR |
| 2022-12-02 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,500 | -$124.8K | EDGAR |
| 2022-11-03 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,500 | -$152.1K | EDGAR |
| 2022-10-05 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,500 | -$166.7K | EDGAR |
| 2022-09-02 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,500 | -$150.8K | EDGAR |
| 2022-08-02 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,500 | -$140.0K | EDGAR |
| 2022-06-02 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −2,500 | -$104.5K | EDGAR |
| 2022-05-03 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | −4,375 | -$108.9K | EDGAR |
| 2022-03-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +6,625 | $15.3K | EDGAR |